8-K: Turn Therapeutics Reports Q1 2026 Results, Secures Growth Capital

Turn Therapeutics announced its first quarter 2026 financial results, highlighting progress in its Phase 2 trial for GX-03 and securing $7 million in growth capital from Avenue Capital Group.

Summary

• Turn Therapeutics reported its financial and operating results for the quarter ended March 31, 2026.
• The company secured an initial $7 million tranche of a growth capital facility from Avenue Capital Group, with up to $25 million available.
• The Phase 2 trial for GX-03 in moderate-to-severe atopic dermatitis (AD) is on track, with interim results expected in Q2 2026 and topline results in mid-2026.
• The company also plans to develop GX-03 for onychomycosis (nail fungus) following the AD program.
• Cash and cash equivalents increased to $11.2 million as of March 31, 2026, from $5.08 million as of December 31, 2025.
• Total operating expenses for Q1 2026 were $1.25 million, a significant increase from $0.38 million in Q1 2025, primarily due to higher R&D and G&A costs.
• The net loss for Q1 2026 was $970,972, compared to a net loss of $328,547 in Q1 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautiously negative sentiment due to increased losses and expenses, despite positive developments in financing and clinical trial progress.

Positives

• Secured $7 million in growth capital from Avenue Capital Group, with potential for an additional $18 million.
• Phase 2 trial for GX-03 in atopic dermatitis remains on schedule with interim results expected in Q2 2026 and topline results in mid-2026.
• Cash and cash equivalents significantly increased to $11.2 million from $5.08 million.
• GX-03 has demonstrated potential for onychomycosis treatment based on in-vivo studies.
• The company believes it is well-positioned to advance clinical programs with near-term catalysts.

Negatives

• Net loss increased to $970,972 in Q1 2026 from $328,547 in Q1 2025.
• Total operating expenses more than tripled to $1.25 million in Q1 2026 from $0.38 million in Q1 2025.
• General and administrative expenses increased significantly to $1.1 million from $0.4 million year-over-year.

Risks

• Risks related to the success of development programs.
• Risks related to the company's ability to execute its strategic plan.
• Uncertainties and assumptions that are difficult to predict regarding future events.
• Potential for the interim analysis of the Phase 2 trial to result in study expansion rather than continuation as designed.

Future Outlook

The company expects interim results for its Phase 2 trial of GX-03 in atopic dermatitis in Q2 2026 and topline results in mid-2026. Additional clinical steps for the onychomycosis program are planned following the completion of the AD program. The Avenue Capital facility provides access to up to $25 million in term loans, with further availability contingent on achieving clinical and corporate milestones.

Management Comments

• "The first quarter of 2026 materially strengthened Turn Therapeutics both operationally and financially," said Bradley Burnam, Chief Executive Officer of Turn Therapeutics.
• "With the Avenue Capital facility now in place, we believe the Company is well positioned to advance our clinical programs through multiple near-term catalysts while maintaining focus on disciplined execution."
• "Our Phase 2 trial evaluating GX-03 in moderate-to-severe atopic dermatitis remains on schedule, with an independent committee expected to assess conditional probability of success at the interim analysis and determine whether the study should continue as designed or expand enrollment based on the strength of the observed trend."
• "We continue to expect topline results in mid-2026 and believe these upcoming milestones have the potential to meaningfully shape the future of both our platform and pipeline."

Industry Context

StockSavvy.ai notes that Turn Therapeutics operates in the competitive clinical-stage biotechnology sector, focusing on dermatologic conditions. The company's progress with GX-03 in atopic dermatitis aligns with industry efforts to develop targeted inflammatory therapies. The secured growth capital is crucial for advancing late-stage clinical trials, a common requirement for companies in this space.

Stakeholder Impact

• Shareholders: Increased net loss and operating expenses may be a concern, but the secured capital and progress in clinical trials offer potential future upside.
• Employees: Continued investment in R&D and G&A suggests ongoing operations and potential for growth.
• Creditors: The secured growth capital facility provides financial stability.

Next Steps

• Conduct interim analysis for the Phase 2 trial of GX-03 in atopic dermatitis in Q2 2026.
• Report topline results for the Phase 2 trial of GX-03 in atopic dermatitis in mid-2026.
• Plan additional clinical steps for the onychomycosis program after the AD program completion.

Key Dates

Recommendation

The company has secured crucial funding and is progressing its lead candidate, which are positive signs. However, the significant increase in net loss and operating expenses, coupled with the inherent risks of clinical-stage biotechnology, warrants a cautious 'hold' recommendation until further clinical data de-risks the asset.

Keywords

Turn Therapeutics, GX-03, Atopic Dermatitis, Onychomycosis, Biotechnology, Clinical Trials, Growth Capital, Financial Results